Literature DB >> 27867509

Comparison of fentanyl iontophoretic transdermal system and routine care with morphine intravenous patient-controlled analgesia in the management of early postoperative mobilisation: results from a randomised study.

Richard M Langford1, Kuang-Yi Chang2, Li Ding3, Jeffrey Abraham3.   

Abstract

INTRODUCTION: Fentanyl iontophoretic transdermal system (ITS) (IONSYS®, The Medicines Company, Parsippany, NJ, USA) and morphine intravenous (IV) patient-controlled analgesia (PCA) have demonstrated equivalent pain control in several published studies. The primary objective of the current study was to compare fentanyl ITS with morphine IV PCA with regard to the patient's ability to mobilise with acute postoperative pain.
METHODS: In this multicentre, open-label, randomised, active-controlled, prospective phase IV study, postoperative patients initially received IV morphine and were titrated to pain score ⩽ 4out of 10 on a Numeric Rating Scale (NRS) and then received fentanyl ITS (up to 240 µg (6 doses)/hour; up to a maximum of 3.2 mg (80 doses)/24 hours) or morphine IV PCA (doses up to 20 mg morphine/2 hours, up to 240 mg/24 hours). The primary efficacy measure was ability to mobilise, assessed using patient responses to three validated questions regarding mobility on a 6-point Likert scale (0 = no difficulty to mobilise to 5 = a very great deal of difficulty to mobilise). The study was originally planned to include ~200 patients. However, following the early suspension and termination of the study, a total of 108 patients were randomised to study treatment.
RESULTS: One hundred and eight patients were recruited prior to undergoing surgical procedures (orthopaedic surgical procedures (72%) or underwent major abdominal procedures (28%)). Postoperatively, 58 were randomised to receive fentanyl ITS, and 50 to morphine IV PCA. Fentanyl ITS patients had a greater ability to mobilise at the time of stopping study drug, with an adjusted mean ability to mobilise score (95% confidence interval (CI)) of 0.14 (-0.19, 0.47) for fentanyl ITS patients and 2.37 (1.98, 2.76) for morphine IV PCA patients (p < 0.001).
CONCLUSION: Patients treated with fentanyl ITS reported that they were better able to mobilise than patients treated with morphine IV PCA, at all time-points following surgery out to 24 hours.

Entities:  

Keywords:  Fentanyl; iontophoretic transdermal system; morphine; patient-controlled analgesia; postoperative mobilisation

Year:  2016        PMID: 27867509      PMCID: PMC5102101          DOI: 10.1177/2049463716668905

Source DB:  PubMed          Journal:  Br J Pain        ISSN: 2049-4637


  23 in total

1.  Improving patient and nurse outcomes: a comparison of nurse tasks and time associated with two patient-controlled analgesia modalities using delphi panels.

Authors:  Christopher Evans; Jeff Schein; Winnie Nelson; Simone Crespi; Kathryn Gargiulo; Nathalie Horowicz-Mehler; Sunil Panchal
Journal:  Pain Manag Nurs       Date:  2007-06       Impact factor: 1.929

Review 2.  Optimising postoperative pain management in the ambulatory patient.

Authors:  Allan B Shang; Tong J Gan
Journal:  Drugs       Date:  2003       Impact factor: 9.546

3.  Development of the fentanyl iontophoretic transdermal system (ITS) for patient-controlled analgesia of postoperative pain management.

Authors:  Harold S Minkowitz; Hassan Danesi; Li Ding; James B Jones
Journal:  Pain Manag       Date:  2015-05-29

4.  Fentanyl iontophoretic transdermal system for acute-pain management after orthopedic surgery: a comparative study with morphine intravenous patient-controlled analgesia.

Authors:  Craig T Hartrick; Michael H Bourne; Kathryn Gargiulo; C V Damaraju; Sue Vallow; David J Hewitt
Journal:  Reg Anesth Pain Med       Date:  2006 Nov-Dec       Impact factor: 6.288

5.  Development and validation of a new instrument to evaluate the ease of use of patient-controlled analgesic modalities for postoperative patients.

Authors:  Gale Harding; Jeff R Schein; Winnie W Nelson; Sue Vallow; William H Olson; David J Hewitt; Rosemary C Polomano
Journal:  J Med Econ       Date:  2010-03       Impact factor: 2.448

Review 6.  Patient-controlled analgesia-related medication errors in the postoperative period: causes and prevention.

Authors:  Jeff R Schein; Rodney W Hicks; Winnie W Nelson; Vanja Sikirica; D John Doyle
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

7.  Design and functionality of a smart fentanyl iontophoretic transdermal system for the treatment of moderate-to-severe postoperative pain.

Authors:  Nitin Joshi; John Lemke; Hassan Danesi
Journal:  Pain Manag       Date:  2016-01-25

8.  Iontophoretic transdermal system using fentanyl compared with patient-controlled intravenous analgesia using morphine for postoperative pain management.

Authors:  S Grond; J Hall; A Spacek; M Hoppenbrouwers; U Richarz; F Bonnet
Journal:  Br J Anaesth       Date:  2007-06       Impact factor: 9.166

Review 9.  Optimal pain management in total abdominal hysterectomy.

Authors:  Laleh Azari; Joseph T Santoso; Shelby E Osborne
Journal:  Obstet Gynecol Surv       Date:  2013-03       Impact factor: 2.347

10.  Patient-controlled analgesia compared with intramuscular injection of analgesics for the management of pain after an orthopaedic procedure.

Authors:  C W Colwell; B A Morris
Journal:  J Bone Joint Surg Am       Date:  1995-05       Impact factor: 5.284

View more
  3 in total

Review 1.  Fentanyl Formulations in the Management of Pain: An Update.

Authors:  Stephan A Schug; Sonya Ting
Journal:  Drugs       Date:  2017-05       Impact factor: 9.546

Review 2.  New Advances in Acute Postoperative Pain Management.

Authors:  Sukanya Mitra; Daniel Carlyle; Gopal Kodumudi; Vijay Kodumudi; Nalini Vadivelu
Journal:  Curr Pain Headache Rep       Date:  2018-04-04

3.  High Body Mass Index and Use of Fentanyl Iontophoretic Transdermal System in Postoperative Pain Management: Results of a Pooled Analysis of Six Phase 3/3B Trials.

Authors:  Eugene R Viscusi; Li Ding; J Bradley Phipps; Loretta M Itri; Philip R Schauer
Journal:  Pain Ther       Date:  2016-12-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.